Offer Document Posted

AstraZeneca PLC
03 May 2007

                              PRESS RELEASE





NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR
FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION



FOR IMMEDIATE RELEASE



3 May 2007



          Recommended Cash Tender Offer for MedImmune by AstraZeneca



Pursuant to the merger agreement with MedImmune, Inc. announced on 23 April,
AstraZeneca PLC announces that its wholly-owned subsidiary, AstraZeneca
Biopharmaceuticals Inc., today commenced a cash tender offer to acquire all
outstanding shares of MedImmune's common stock, par value $0.01 per share, at a
price of $58.00 per share.  The tender offer is scheduled to expire at 12:00
Midnight, New York City time, on Thursday, 31 May 2007, unless extended. Details
of the tender offer are contained in the documents that are being sent to
MedImmune stockholders and will be posted on astrazeneca.com.



Enquiries:



AstraZeneca

Media Enquiries:

Steve Brown / Edel McCaffrey (London)             [phone]/5034
Staffan Ternby (Sweden)                           [phone]
Emily Denney (Wilmington)                         [phone]

Analyst/Investor Enquiries:

Jonathan Hunt / Mina Blair / Karl Hard (London)   [phone]/5084/5322
Staffan Ternby (Sweden)                           [phone]
Ed Seage / Jorgen Winroth                         [phone] / 
                                                  [phone]

Merrill Lynch (Financial Adviser to AstraZeneca)  [phone]
Richard Girling

Deutsche Bank (Joint Corporate Broker to AstraZeneca)   [phone]
Charlie Foreman

Goldman Sachs (Joint Corporate Broker to AstraZeneca)   [phone]
Phil Raper


                      This information is provided by RNS
            The company news service from the London Stock Exchange